Literature DB >> 12477415

Safety and immunogenicity of influenza vaccination in individuals infected with HIV.

Alessandro R Zanetti1, Antonella Amendola, Silvia Besana, Antonio Boschini, Elisabetta Tanzi.   

Abstract

Influenza can cause severe complications in HIV infected individuals leading to increases in hospitalisation and mortality. Vaccination is recommended for such individuals, but some studies reported that immunisation against influenza may stimulate an increase of HIV viral load and decrease of CD4+ cells count. A review of published studies, including our study carried out in HIV former drug addicts, indicates that vaccination against influenza is well tolerated in both children and adult individuals with HIV, but response to vaccination is lower than that observed in immunocompetent individuals. Most studies, including our own, show that vaccination does not induce significant changes in viral load and CD4+ cell counts. In studies reporting modifications of such parameters there is a general agreement that the increased viral replication is usually transient and unable to determine a clear, measurable progression of the underlying HIV disease. Therefore, vaccination against influenza can be safely administered to HIV infected people.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477415     DOI: 10.1016/s0264-410x(02)00511-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

Review 1.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

2.  Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore.

Authors:  Yuk-Fai Lau; Lay-Hoon Tang; David Chien Lye; Eng-Eong Ooi; Yee-Sin Leo
Journal:  Hum Vaccin Immunother       Date:  2017-02-17       Impact factor: 3.452

3.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

4.  Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients.

Authors:  Chiara Agrati; Cristiana Gioia; Concetta Castilletti; Daniele Lapa; Giulia Berno; Vincenzo Puro; Fabrizio Carletti; Eleonora Cimini; Carla Nisii; Flora Castellino; Federico Martini; Maria R Capobianchi
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-08       Impact factor: 2.205

Review 5.  Effect of treating co-infections on HIV-1 viral load: a systematic review.

Authors:  Kayvon Modjarrad; Sten H Vermund
Journal:  Lancet Infect Dis       Date:  2010-07       Impact factor: 25.071

Review 6.  Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic.

Authors:  Anandi N Sheth; Pragna Patel; Philip J Peters
Journal:  Curr HIV/AIDS Rep       Date:  2011-09       Impact factor: 5.071

7.  Pandemic influenza is a strong motivator for participation in vaccine clinical trials among HIV-positive Canadian adults.

Authors:  Mb Kiberd; C Cooper; Jm Slaunwhite; B Halperin; D Haase; Sa McNeil
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

Review 8.  Immunization in patients with HIV infection: are practical recommendations possible?

Authors:  Brian Eley
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults.

Authors:  P Durando; D Fenoglio; A Boschini; F Ansaldi; G Icardi; L Sticchi; A Renzoni; P Fabbri; A Ferrera; A Parodi; B Bruzzone; G Gabutti; A Podda; G Del Giudice; E Fragapane; F Indiveri; P Crovari; R Gasparini
Journal:  Clin Vaccine Immunol       Date:  2007-11-14

10.  A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings.

Authors:  Rebecca Pellett Madan; Maria Tan; Ana Fernandez-Sesma; Thomas M Moran; Sukru Emre; Andrew Campbell; Betsy C Herold
Journal:  Clin Infect Dis       Date:  2008-03-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.